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Abstract
Background: Visceral leishmaniasis (VL) is an important and potentially fatal neglected tropical disease. The aim
of this study was to investigate hyponatremia and risk factors for death among VL patients.
Methods: This is a cross-sectional study with VL patients admitted to a tertiary hospital in Northeast Brazil, from
2002 to 2009. Patients were divided into two groups: non-survivors and survivors. Hyponatremia was defined as
serum sodium < 135 mEq/L. A logistic regression model was done to investigate risk factors for death.
Results: A total of 285 VL patients were included, with mean age 37 ± 15 years, and 74% were males. Thirty-four
patients died (11.9%). Non-survivors had a significantly higher prevalence of dyspnea (38.2 vs. 16.7%, p = 0.003),
pulmonary crackles (11.8 vs. 4.0%, p = 0.049), dehydration (23.5 vs. 10.8%, p = 0.033), oliguria (8.8 vs. 0.8%, p = 0.001)
and jaundice (47.1 vs. 14.3%, p < 0.001). They also presented higher prevalence of hyponatremia (41.9 vs. 24.1%,
p = 0.035), thrombocytopenia (91.2 vs. 65.3%, p = 0.002) and severe hypoalbuminemia (78.3 vs. 35.3%, p < 0.001). In
multivariate analysis, moderate/severe hyponatremia (OR = 2.278, 95% CI = 1.046–4.962), thrombocytopenia (OR = 5.
482, 95% CI = 1.629–18.443), jaundice (OR = 5.133, 95% CI = 1.793–14.696) and severe hypoalbuminemia (OR = 6.479,
95% CI = 2.124–19.766) were predictors of death.
Conclusion: Higher prevalence of dehydration, oliguria, pulmonary symptoms and liver involvement was found in
non-survivors VL patients. Hypoalbuminemia and hyponatremia were frequent and significantly associated with mortality.
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Background
Visceral Leishmaniasis (VL), also known as kala-azar, is
a zoonosis caused by protozoan parasites from the genus
Leishmania, which are typically found in tropical areas.
The disease is endemic in many countries, including
Brazil, which responds for 90% of cases in the Americas
[1]. Due to its high incidence and the potential harms
caused by the illness, it has become one of the World
Health Organization’s (WHO) top priorities among
neglected tropical diseases [2].
The Leishmania parasites escape the hosts’ immune re-
sponse and cause a severe immune dysfunction, with poly-
clonal activation of B lymphocytes as well as cellular and
humoral immunity impairment. During the progression of
the disease, the parasites affect reticuloendothelial tissues
and important organs, such as lymph nodes, bone mar-
row, liver, spleen, digestive system and kidneys [3]. This
condition predominantly affects children and young
adults, and may manifest as an oligosymptomatic infection
with non-specific symptoms such as low fever, dry cough-
ing, sweating and malaise, or as a life-threatening chronic
condition with pancytopenia, hemorrhagic phenomena,
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hepatomegaly, splenomagly, hypoalbuminemia and ele-
vated globulinemia [4, 5].
Unfortunately, mortality from VL is still unacceptable
high, reaching 95% when untreated [5]. There are some
studies investigating factors associated with poor out-
come in VL. A recent study from India evidenced some
epidemiologic aspects as associated with less mortality
in VL: treatment at public facility, shorter (≤30 days)
diagnostic delay and treatment completion [6]. Other
studies found some clinical aspects as risk factors for
death in VL, such as: secondary bacterial infections,
edema, jaundice, thrombocytopenia, hemorrhage, diar-
rhea, age (young children or elderly), severe neutropenia,
dyspnea, and hypoalbuminemia, among others [7–10].
Hence, the aim of this study was to investigate hypo-
natremia and risk factors for death among VL patients.
Methods
Studied population
This is a cross-sectional study conducted with VL
patients consecutively admitted to the São José Infec-
tious Diseases hospital in Fortaleza, Ceará, Brazil, from
January 2002 to December 2009. All VL cases admitted
in the study period were included. This hospital is a ref-
erence for all infectious diseases in the state of Ceará,
Northeast Brazil, which is endemic for VL. All patients
had clinical and epidemiological data suggestive of VL.
Diagnosis was confirmed by immunofluorescence, react-
ive in serology test using K39 antigen or the presence of
amastigote forms of the parasite in the bone marrow
smears. Inclusion criteria were: VL confirmed diagnosis
and age ≥ 15 years, due to differences in laboratory and
acute kidney injury (AKI) definition for the pediatric
population.
In order to perform a comparison, patients were di-
vided into two different groups: non-survivors (included
patients who died during hospitalization) and survivors
(included the patients who did not).
Treatment protocol
According to the treatment protocol from the Brazilian
Ministry of Health, patients were treated with pentavalent
antimonial (meglumine antimoniate - Glucantime®) 20 mg/
kg daily for 20 to 40 consecutive days. In cases of unsuc-
cessful treatment with pentavalent antimonial or toxicity to
this drug, amphotericin B (0.7 – 1.0/kg) daily for 14 to 21
consecutive days was indicated. However, amphotericin B
was indicated as the first line drug in some cases: deterio-
rated clinical status, age > 50 years, QT interval > 450 ms
on electrocardiography or use of medication which enlarge
QT interval, allergy to pentavalent antimonial, immune de-
ficiencies or use of immune suppressors and pregnant
women. The formulation of amphotericin B used (liposo-
mal or deoxycholate) depended on drug availability during
hospitalization. None of the researchers interfered with
drug choice.
Clinical and demographical parameters included age,
gender, hospitalization time, time between onset of
symptoms and hospitalization, main signs and symptoms
on admission, treatments and AKI development. Treat-
ment parameters included a record of all VL drug
therapies initiated after hospital admission.
Biochemical evaluation
Biochemical analyses were performed using a routine
automated analyzer (Cobas C111, Roche®), including
serum urea and creatinine, albumin, globulins, aspartate
amino transaminase (AST), alanine amino transaminase
(ALT), total bilirubin, indirect bilirubin, direct bilirubin.
Serum urea in samples was hydrolyzed by urease to
form ammonia that reacts with alfa-ketoglutarate and
NADH in the presence of GLDH enzyme. The decrease
in absorbance due to consumption of NADH is propor-
tional to urea levels. Serum creatinine was quantified by
colorimetric assay based on the Jaffé method. In alkaline
solution, creatinine forms a yellow-red complex with
picrate. The rate of dye formation is proportional to the
creatinine concentration in the specimen. Also, serum
albumin, globulins, AST, ALT, total, direct and indirect
bilirubin were determined by colorimetric assay.
Sodium and potassium were determined by ion select-
ive electrolyte analyzer (9180, Electrolyte Analyzer,
Roche®) and expressed as mEq/L.
Hemoglobin (Hb), hematocrit, leukocytes count,
platelets count were determined by Automated Hemato-
logyDiagnostics (Sysmex® XT4000i). Arterial blood gas
analysis included pH, arterial carbon dioxide partial
pressure (pCO2) and bicarbonate (HCO3) were deter-
mined through “Blood gas analyzer” machine (Stat Profile
Prime® Critical Care Analyser).
Definitions
AKI was defined according to Kidney Diseases Improving
Global Outcomes (KDIGO) criteria [11]. Hypotension was
defined as mean arterial blood pressure (MAP) < 60 mmHg,
and therapy with vasopressors was initiated when the MAP
remained < 60 mmHg despite of fluid administration.
Oliguria was defined as urine output < 0.5 mL/kg/h after
adequate fluid replacement.
Hyponatremia was defined as serum sodium (Na+) <
135 mEq/L. Patients were classified among hyponatre-
mia severity: mild hyponatremia was defined as Na+
between 134 and 131 mEq/L, moderate hyponatremia as
Na+ between 130 and 126 mEq/L and severe hyponatre-
mia as Na+ ≤ 125 mEq/L. Hypokalemia was defined as
serum potassium < 3.5 mEq/L. Anemia was defined as
Hb < 13.0 g/dL in males and Hb < 12.0 g/dL in females.
Leukopenia was defined as leukocytes < 4,000/mm3 and
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thrombocytopenia as platelets < 100,000/mm3. Hypoalbu-
minemia was defined as serum albumin < 3.5 g/dL and
severe hypoalbuminemia as serum albumin < 2.5 g/dL.
Statistical analysis
Statistical analysis was executed using SPSS program for
windows version 20.0 (IBM, Chicago – IL, USA) and its
results were expressed through tables. Kolmogorov-
Smirnov test was used for numeric variables, in order to
assess variable distribution. Variables with normal distri-
bution were expressed through mean ± standard devi-
ation (SD). Variables with non-normal distribution were
expressed through median values. Patients were divided
into two groups in order to perform a comparison: those
patients who died (non-survivors) and those who did
not (survivors). Comparison of categorical variables was
executed using Pearson’s Chi-square while numerical
variables were compared using Student’s T test (for vari-
ables with normal distribution) or Mann-Whitney test
(for variables with non-normal distribution). P values ≤
0.05 were considered statistically significant. In order to
evaluate risk factors or protective factors for death, a
logistic regression model was used for categorical vari-
ables. Adjusted odds ratios (OR) and 95% confidence
intervals (CI) were calculated. All variables which
presented statistical significance (p ≤ 0.05) in the univari-
ate analysis were included in the logistic regression.
Results
In the studied period, 285 patients with VL were admit-
ted, with mean age of 37 ± 15.3 years, and 74% were
males. Among them, 34 died (11.9%). There was not any
difference between survivors and non-survivors regard-
ing age, gender, hospitalization time or time between on-
set of symptoms and hospitalization, as summarized in
Table 1.
Regarding treatment, the majority of patients were exclu-
sively treated with pentavalent antimonial (68.2%). Seventy-
seven patients (27%) used deoxycholate amphotericin B
and 14 (4.8%) used liposomal amphotericin B. Frequency of
exclusive pentavalent antimonial treatment was significantly
lower in non-survivors than survivors (50.0% vs.
70.5%, p = 0.003), but pentavalent antimonial use was
not a protective factor for death in multivariate
analysis.
Non-survivors presented a significantly higher preva-
lence of vomiting (38.2 vs. 21.5%, p = 0.031), dehydra-
tion (23.5 vs. 10.8%, p = 0.033), edema (32.4 vs. 16.7%,
p = 0.028), oliguria (8.8 vs. 0.8%, p = 0.001), dyspnea
(38.2 vs. 16.7%, p = 0.003), pulmonary crackles (11.8 vs.
4.0%, p = 0.049) and jaundice (47.1 vs. 14.3%, p < 0.001)
on admission, as presented in Table 2. They also had
higher prevalence of moderate hyponatremia (41.9
vs. 24.1%, p = 0.035), thrombocytopenia (91.2 vs.
65.3%, p = 0.002) and severe hypoalbuminemia (78.3
vs. 35.3%, p < 0.001).
Acute kidney injury (AKI) was observed in 93 patients
(32.6%). Among AKI patients, most of them were in
stage 2 (41.9%) or stage 3 (40.8%) according to KDIGO
classification, but there was not significant differences
between groups in AKI development.
In addition, non-survivors had significantly lower levels
of hemoglobin (6.5 ± 1.8 vs. 7.5 ± 1.5 g/dL, p < 0.001),
hematocrit (20.4 ± 5.0 vs. 23.1 ± 4.6%, p = 0.002), leuko-
cytes count (3904 vs. 3688/mm3, p = 0.01), platelets count
(32.0 ± 28.6 vs. 84.0 ± 62.1 103/mm3, p = 0.017), serum
sodium (130.6 ± 5.4 vs. 133.2 ± 4.2 mEq/L, p = 0.005) and
serum albumin (2.04 ± 0.74 vs. 2.70 ± 0.79 g/dL, p < 0.001),
as well as higher levels of AST (median: 295 vs. 104 IU/
L, p = 0.039), total bilirubin (median: 7.0 vs. 1.3 mg/dL,
p < 0.001), indirect bilirubin (median: 5.4 vs. 0.9 mg/dL,
p < 0.001), direct bilirubin (median: 1.6 vs. 0.4 mg/dL,
p = 0.004) and PCO2 (median: 36.7 ± 10.1 vs. 31.6 ±
6.2 mmHg, p = 0.044), as demonstrated in Table 3.
There was not significant difference in serum urea,
creatinine, potassium, globulins, ALT, arterial pH and
bicarbonate.
Multivariate analysis showed that jaundice (p = 0.002,
OR = 5.133, 95% CI = 1.793–14.696), thrombocytopenia
(p = 0.006, OR = 5.482, 95% CI = 1.629–18.443), severe
hypoalbuminemia (p = 0.001, OR = 6.479, 95% CI = 2.124–
19.766) and moderate/severe hyponatremia (p = 0.038,
OR = 2.278, 95% CI = 1.046–4.962) on admission were im-
portant risk factors for death, as evidenced in Table 4.
Discussion
VL is an important zoonotic disease which presents an
alarmingly elevated prevalence in the Brazilian state of
Ceará, where this research was conducted [1]. This dis-
ease presents a broad spectrum of symptoms, which
may vary from an oligosymptomatic infection to a life-
threatening chronic condition [5]. This is one of the few
studies to investigate the role of hyponatremia in VL
Table 1 Comparison of demographic data between survivors






Age (years) 42.8 ± 19.5 36.3 ± 14.6 0.067
Gender
Male 26 (76.5%) 185 (77.7%) 0.873
Female 8 (23.5%) 56 (22.3%)
Time between onset of symptoms
and admission (days)
94 (5–730) 87 (1–720) 0.422
Hospitalization time (days) 21 (2–66) 20 (2–221) 0.469
Values were represented as mean ± SD, median (range) or percentages.
Student’s T test and Chi-squared tests were used. P ≤ 0.05 was considered
statistically significant
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and the first to found a significant association of this
disturbance with mortality in VL.
VL clinical manifestations are dependent on host’s
immune response. When type I immune response is
triggered, in general, there is effective protection against
Leishmanias, due to activation of infected phagocytes,
which leads to destruction of intracellular amastigotes
[12]. Disease can progress due to multiple factors that
block adequate response, including the action of sup-
pressive cytokines, exhaustion of specific T cells, loss of
lymphoid tissue architecture and a defective humoral
response [12]. In the present study it was not possible to
assess patients’ immune response because this is not
routine in our hospital.
The patients in our study were mostly treated with
pentavalent antimonials (PA), according to treatment
protocol from Brazilian Ministry of Health. This type of
drug has well known adverse effects, such as cardiac,
renal and pancreatic toxicities. It enters the host cells
and kills amastigote forms of the parasite, but also in-
duces DNA toxicity and cellular necrosis in the human
host [13, 14]. In the present study, non-survivors used
significantly less PA than survivors. Differently from
what was found in previous studies, PA use and its side-
effects were not associated with increased mortality risk
in our cohort [15]. Patients who needed a second line
drug (amphotericin B) were those who had contraindica-
tions to PA or presented a poorer clinical status, leading
to higher propensity for mortality.
Regarding symptoms, non-survivors presented vomit-
ing, dehydration and oliguria more frequently, reflecting
the volume depletion they manifested on admission.
However, it did not lead to important hemodynamic
instability, since most of the patients did not present
hypotension or other cardiovascular abnormality. This
hypovolemic state may have contributed to hyponatre-
mia development, due to vasopressin secretion, and
stimulus of renin-angiotensin-aldosterone system, as
suggested by others [3].
In addition, non-survivors manifested higher preva-
lence of pulmonary symptoms on admission, such as
dyspnea and pulmonary crackles, as well as significantly
higher CO2 partial pressure on arterial blood gas ana-
lysis. Lung involvement in VL has been previously
Table 2 Comparison of main signs and symptoms between






Fever 30 (88.2%) 229 (91.2%) 0.569
Hepato-splenomegaly 22 (64.7%) 199 (79.3%) 0.056
Weight loss 22 (64.7%) 185 (74%) 0.253
Asthenia 16 (47.1%) 156 (62.2%) 0.091
Cough 13 (38.2%) 95 (37.8%) 0.965
Abdominal pain 15 (44.1%) 84 (33.5%) 0.221
Diarrhea 12(35.3%) 57 (22.7%) 0.108
Vomiting 13 (38.2%) 54 (21.5%) 0.031
Dyspnea 13 (38.2%) 42 (16.7%) 0.003
Edema 11 (32.4%) 42 (16.7%) 0.028
Jaundice 16 (47.1%) 36 (14.3%) <0.001
Dehydration 8 (23.5%) 27 (10.8%) 0.033
Nose bleeding 11 (4.8%) 13 (5.2%) 0.128
Pulmonary crackles 4 (11.8%) 10 (4.0%) 0.049
Oliguria 3 (8.8%) 2 (0.8%) 0.001
Hypotension 0 (0%) 2 (0.8%) 0.602
Chi-squared test was used. P ≤ 0.05 was considered statistically significant
Table 3 Comparison of laboratory data, at hospital admission,







Hemoglobin (g/dL) 6.5 ± 1.8 7.5 ± 1.5 < 0.001
Hematocrit (%) 20.4 ± 5.0 23.1 ± 4.6 0.002
Leukocytes (/mm3) 3904 (900–16,800) 3688 (300–11,000) 0.01
Platelets (103/mm3) 32.0 ± 28.6 84.0 ± 62.1 0.017
Urea (mg/dL) 57.1 ± 37.9 51.8 ± 38.9 0.469
Creatinine (mg/dL) 1.07 ± 0.47 1.15 ± 1.13 0.750
Sodium (mEq/L) 130.6 ± 5.4 133.2 ± 4.2 0.005
Potassium (mEq/L) 4.2 ± 0.8 4.0 ± 0.6 0.297
Albumin (g/dL) 2.04 ± 0.74 2.70 ± 0.79 < 0.001
Globulins (g/dL) 4.26 ± 1.26 4.32 ± 1.65 0.915
AST (U/L) 295 (12–2161) 104 (13–1165) 0.039
ALT (U/L) 192 (5–1071) 78 (4–603) 0.065
Total bilirubin (mg/dL) 7.0 (1.0–22.3) 1.3 (0.04–21.1) < 0.001
Direct Bilirubin (mg/dL) 5.4 (0.66–17.79) 0.9 (0.07–16.7) < 0.001
Indirect Bilirubin (mg/dL) 1.6 (0.08–7.0) 0.4 (0.06–4.4) 0.04
Arterial pH 7.34 ± 0.14 7.44 ± 0.06 0.059
HCO3 (mEq/L) 16.7 ± 7.1 20.7 ± 6.5 0.178
PCO2 (mmHg) 36.7 ± 10.1 31.6 ± 6.2 0.044
AST aspartate aminotransferase, ALT alanine aminotransferase, HCO3 serum
bicarbonate, PCO2 carbon dioxide partial pressure
Values were represented as mean ± SD or median (range). Student’s T test and
Mann-Whitney tests were used. P ≤ 0.05 was considered statistically significant
Table 4 Risk factors for death among survivors and non-survivors
patients with visceral leishmaniasis
OR 95% CI p
Hypoalbuminemia (severe) 6.479 2.124–19.766 0.001
Thrombocytopenia 5.482 1.629–18.443 0.006
Jaundice 5.133 1.793–14.696 0.002
Hyponatremia (moderate/severe) 2.278 1.046–4.962 0.038
OR Odds Ratio, CI Confidence Interval
P ≤ 0.05 was considered statistically significant
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noticed, usually persisting from beginning through the
entire course of the disease. It usually presents as inter-
stitial pneumonitis, but also may manifest as pleural
effusions or secondary lobar pneumonia [16]. In a study
with 50 children with VL, secondary bacterial lobar
pneumonia was diagnosed in 10% of cases [17]. Studies
have demonstrated that both mononuclear infiltrates in
the interstitial space and B lymphocytes activation with
Th2 immune pattern response may be responsible for
VL pneumonitis [18, 19]. Interstitial pneumonitis has
also been associated to syndrome of inappropriate anti-
diuretic hormone secretion (SIADH) development in VL
patients, resulting in hyponatremia [3].
Interestingly, AKI prevalence was high, but there was
not significant differences between groups, even though
renal failure have been previously described as risk
factor for death in VL patients [20]. Renal involvement
in VL is usually mild and transitory, but loss of kidney
function may happen in some cases [5, 21]. However,
the majority of our patients presented moderate to
severe forms of AKI. We believe that use of nephrotoxic
VL treatments may have been key factors on AKI devel-
opment instead of hemodynamic factors, leading to no
differences between groups.
Jaundice, hypoalbuminemia and hyponatremia were
significantly more prevalent in non-survivors, and they
were risk factors for death in multivariate analysis. Jaun-
dice may reflect both liver involvement in VL and
hemolysis, since both direct and indirect bilirubin were
elevated. Total bilirubin, alkaline phosphatase and AST
were also significantly higher in non-survivors. Liver is
one of main reticuloendothelial organs affected by kala-
azar (others are spleen and bone marrow), due to the
presence of mononuclear macrophage system cells, as
well as hepatic stellar cells [22]. The most frequently
observed form of hepatic involvement in VL is hepato-
megaly with chronic elevation of transaminases and bili-
rubins, due to direct infection by the parasite as well as
hepatotoxicity of some medications, but it may rarely
presents as acute liver disease [23, 24]. VL causes several
changes in the liver, which leads to mononuclear cell in-
filtration, hepatocyte degeneration and fibrosis [25, 26].
The occurrence of jaundice was the strongest risk factor
for severity in VL patients in a recent meta-analysis [7].
Thrombocytopenia has been previously recognized as a
factor associated to adverse outcomes. In an important
Brazilian meta-analysis, thrombocytopenia was a strong
predictor of death among VL patients, a risk that was in-
tensified in patients with platelets < 50,000/mm3 [7].
Low platelet count may be attributed to splenic platelets
sequestration and systemic inflammation caused by VL
parasites [27, 28]. In a recent study, thrombocytopenia
was associated to elevated levels of IL-27, IL-10 and IL-6
cytokines. These cytokines interfere with macrophage
activity and cause an impairment of Th1 response,
predisposing to Leishmania proliferation and higher risk
of unfavorable outcomes [29].
Hypoalbuminemia was very prevalent among our
patients, and 40.5% of them presented severe hypoalbu-
minemia (serum albumin < 2.5 g/dL). Hypoalbuminemia
in VL derives from hepatic dysfunction, impaired albu-
min production and reduced intestinal absorption of
proteins due to protein loosing enteropathy [30]. These
findings corroborate data in the literature, since albumin
has been described as a factor for VL severity. In a
Brazilian meta-analysis, low levels of albumin and the
presence of edema were risk factors for severity and
death in VL patients [7]. In another cohort study with
VL children, serum albumin levels < 2.5 g/dL on admis-
sion were risk factors for poor outcomes [8]. Hyponatre-
mia can be considered as the most frequent electrolyte
disturbance in hospitalized patients and also in VL [31].
It has been described in a large variety of clinical situa-
tions, including medication related, cardiac, renal,
hepatic and auto-immune conditions, as well as post-
surgical conditions [32–36]. Low sodium levels are
remarkably prevalent in infectious diseases, including
viral, fungal, bacterial and protozoan infection [31]. In
VL, hyponatremia prevalence > 90% was reported before
[37]. Despite of that, there are scarce data in the litera-
ture relating hyponatremia to VL and there are not
previous studies that describe hyponatremia as risk
factors for death in kala-azar.
The pathogenesis of hyponatremia in VL is extremely
complex and involves several hemodynamic and hormo-
nal factors, as described in Fig. 1. Reduced body water
may be considered the initial factor for hyponatremia in
some patients, especially those who presented vomiting,
diarrhea and clinical dehydration on admission. This vol-
ume depletion may lead to serum osmolality increase
and vasopressin release, as well as renin-angiotensin-
aldosterone system activation, leading to hyponatremia
[1, 31]. Renal Na+ loss may also be considered a mech-
anism for hyponatremia. In a case series of 55 patients
with VL, 15% of them had increased fractional excretion
of sodium [36]. Tubular dysfunction is frequent in both
visceral and cutaneous leishmaniasis which can contrib-
ute to hyponatremia development [38, 39]. Hypergam-
maglobulinemia, due to polyclonal activation of B
lymphocytes, may also have contributed for hyponatre-
mia. Gamma globulins occupy the space in serum
volume, leading to lower readings of sodium and free
water in serum plasma, a phenomenon called pseudo
hyponatremia [31].
On the other hand, for patients who did not present
dehydration on admission, hyponatremia may result
from syndrome of inappropriate antidiuretic hormone
secretion (SIADH), which is very common among VL
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patients [3]. This syndrome is characterized by hypona-
tremia and hypo-osmolality in normovolemic or hyper-
volemic patients. These patients usually present edema,
as a result of total body water expansion, and preserve
their renal water reabsorption mechanism [40, 41].
SIADH may be caused by medications, but most likely
derives from the intense inflammatory response gener-
ated by multiple organ involvement in VL, which leads
to activation of hypothalamic-pituitary axis and
antidiuretic hormone release [42, 43]. Severe hypoalbu-
minemia, a condition very prevalent among our patients,
may have also aggravated edema and contributed to
hyponatremia development. Low serum albumin reduces
plasma colloidosmotic pressure and reduces intravascu-
lar negative charges, inducing lower sodium attraction
to intravascular space [3].
Conclusions
Higher prevalence of dehydration, oliguria, pulmonary
symptoms and liver involvement is found in non-
survivors VL patients. They manifested higher rates of
jaundice, thrombocytopenia, hypoalbuminemia and
hyponatremia, which were the main predictors of death.
Hyponatremia was frequent and significantly associated
with mortality. Pathogenesis of hyponatremia in VL is
multifactorial and involves both hypovolemic and hyper-
volemic conditions, as well as hypoalbuminemia and
systemic inflammation. Renal tubular dysfunction may
also play a role in VL-associated hyponatremia.
Study limitations
The main limitations of this study derive from its retro-
spective nature. Patients’ data were collected from med-
ical charts, and we unfortunately did not have access to
some of patients’ information. The significant difference
in the number of patients in each group may be consid-
ered a limitation, since it makes statistical analysis more
difficult. However, we have chosen to compare these
groups in order to investigate factors associated to
mortality. Further studies are required to fully under-
stand the pathophysiology of VL-associated hyponatremia
and the best ways to prevent and treat this condition.
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